TABLE 4. Annual reported cases of notifiable diseases and rates, by age group, United States, excluding U.S. Territories and Non-U.S. Residents, 2023

Disease	<1 yr		1-4 yrs		5-14 yrs		15-24 yrs		25-39 yrs		40-64 yrs		65+ yrs		Age not stated	Total
	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	No.
Anthrax	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Arboviral diseases																
Chikungunya virus disease	—	—	—	—	4	0.01	10	0.02	41	0.06	78	0.07	17	0.03	—	150
Eastern equine encephalitis virus disease																
Neuroinvasive	—	—	1	0.01	1	0.00	—	—	—	—	2	0.00	3	0.01	—	7
Non-neuroinvasive	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Jamestown Canyon virus disease																
Neuroinvasive	—	—	1	0.01	2	0.00	2	0.00	1	0.00	6	0.01	8	0.01	—	20
Non-neuroinvasive	—	—	—	—	—	—	—	—	—	—	5	0.00	2	0.00	—	7
La Crosse virus disease																
Neuroinvasive	—	—	9	0.06	23	0.06	—	—	1	0.00	—	—	1	0.00	—	34
Non-neuroinvasive	—	—	—	—	—	—	—	—	—	—	—	—	1	0.00	—	1
Powassan virus disease																
Neuroinvasive	—	—	2	0.01	2	0.00	—	—	1	0.00	13	0.01	29	0.05	—	47
Non-neuroinvasive	—	—	—	—	—	—	—	—	—	—	2	0.00	—	—	—	2
St. Louis encephalitis virus disease																
Neuroinvasive	—	—	—	—	—	—	1	0.00	2	0.00	5	0.00	6	0.01	—	14
Non-neuroinvasive	—	—	—	—	—	—	—	—	—	—	4	0.00	3	0.01	—	7
West Nile virus disease																
Neuroinvasive	—	—	3	0.02	15	0.04	27	0.06	139	0.20	705	0.68	902	1.52	—	1,791
Non-neuroinvasive	1	0.03	2	0.01	6	0.01	24	0.05	121	0.18	425	0.41	260	0.44	—	839
Western equine encephalitis virus disease																
Neuroinvasive	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Non-neuroinvasive	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Babesiosis																
Confirmed	3	0.10	10	0.08	35	0.10	48	0.13	203	0.35	1,143	1.27	1,674	3.28	—	3,116
Probable	—	—	5	0.04	11	0.03	17	0.05	54	0.09	180	0.20	203	0.40	—	470
Total	3	0.10	15	0.12	46	0.13	65	0.17	257	0.44	1,323	1.47	1,877	3.67	—	3,586
Botulism																
Foodborne	—	—	—	—	—	—	1	0.00	3	0.00	9	0.01	4	0.01	—	17
Infant	173	4.74	—	—	—	—	—	—	—	—	—	—	—	—	1	174
Other (wound & unspecified)	—	—	—	—	—	—	1	0.00	2	0.00	5	0.00	6	0.01	—	14
Total	173	4.74	—	—	—	—	2	0.00	5	0.01	14	0.01	10	0.02	1	205
Brucellosis	—	—	4	0.03	5	0.01	9	0.02	26	0.04	60	0.06	41	0.07	—	145
Campylobacteriosis	1,822	49.94	6,460	43.47	4,842	11.81	7,312	16.66	14,793	21.74	26,369	25.30	19,920	33.62	29	81,547
Candida auris																
Clinical*	—	—	2	0.01	—	—	36	0.09	238	0.38	1,184	1.24	1,740	3.26	—	3,200
Screening†	—	—	1	0.01	—	—	53	0.12	296	0.43	1,667	1.60	2,348	3.96	1	4,366
Carbapenemase-producing organisms (CPO), total‡, §	8	0.27	16	0.13	26	0.08	108	0.30	481	0.86	2,465	2.86	3,805	7.73	1	6,910
Chancroid	—	—	—	—	—	—	1	0.00	1	0.00	1	0.00	1	0.00	—	4
Chlamydia trachomatis infection	355	9.73	115	0.77	11,704	28.56	919,819	2095.90	564,876	830.10	112,641	108.07	3,789	6.40	35,145	1,648,444
Cholera	—	—	2	0.01	1	0.00	1	0.00	1	0.00	9	0.01	5	0.01	—	19
Coccidioidomycosis¶																

TABLE 4. Annual reported cases of notifiable diseases and rates, by age group, United States, excluding U.S. Territories and Non-U.S. Residents, 2023

Disease	<1 yr		1-4 yrs		5-14 yrs		15-24 yrs		25-39 yrs		40-64 yrs		65+ yrs		Age not stated	Total
	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	No.
Confirmed	13	0.85	52	0.83	510	2.91	1,559	8.34	3,675	12.84	8,377	19.19	6,492	26.03	7	20,685
Probable	1	0.07	1	0.02	1	0.01	19	0.10	29	0.10	139	0.32	137	0.55	—	327
Total	14	0.92	53	0.84	511	2.92	1,578	8.44	3,704	12.94	8,516	19.51	6,629	26.58	7	21,012
Coronavirus Disease 2019 (COVID-19)																
Confirmed	174,708	5565.66	146,178	1144.64	255,298	724.81	466,448	1242.22	923,402	1574.19	1,529,823	1713.23	1,395,474	2777.09	4,920	4,896,251
Probable#	41,258	1314.35	53,521	419.09	146,927	417.13	285,559	760.49	474,768	809.37	809,687	906.76	658,440	1310.34	4,011	2,474,171
Total	215,966	6880.01	199,699	1563.74	402,225	1141.94	752,007	2002.70	1,398,170	2383.56	2,339,510	2619.99	2,053,914	4087.43	8,931	7,370,422
Cryptosporidiosis																
Confirmed	84	2.30	1,096	7.37	933	2.28	1,393	3.17	2,948	4.33	2,687	2.58	1,442	2.43	1	10,584
Probable	21	0.58	220	1.48	249	0.61	329	0.75	687	1.01	709	0.68	507	0.86	4	2,726
Total	105	2.88	1,316	8.85	1,182	2.88	1,722	3.92	3,635	5.34	3,396	3.26	1,949	3.29	5	13,310
Cyclosporiasis	—	—	19	0.14	52	0.14	248	0.60	1,083	1.69	2,190	2.24	871	1.58	—	4,463
Dengue virus infections**																
Dengue	2	0.05	11	0.07	121	0.30	185	0.42	450	0.66	937	0.90	238	0.40	—	1,944
Dengue-like illness	—	—	—	—	3	0.01	1	0.00	5	0.01	7	0.01	7	0.01	—	23
Severe dengue	—	—	1	0.01	3	0.01	7	0.02	9	0.01	28	0.03	5	0.01	—	53
Diphtheria	—	—	—	—	—	—	1	0.00	—	—	1	0.00	—	—	—	2
Ehrlichiosis and Anaplasmosis																
Anaplasma phagocytophilum infection	—	—	22	0.15	89	0.23	136	0.32	533	0.81	2,654	2.64	3,845	6.73	—	7,279
Ehrlichia chaffeensis infection	1	0.03	8	0.06	51	0.13	60	0.14	160	0.24	792	0.79	835	1.46	—	1,907
Ehrlichia ewingii infection	—	—	—	—	—	—	—	—	3	0.00	15	0.02	8	0.01	—	26
Undetermined ehrlichiosis/ anaplasmosis	—	—	—	—	2	0.01	2	0.00	8	0.01	26	0.03	51	0.09	—	89
Giardiasis	106	3.73	1,139	9.82	1,605	5.01	1,467	4.26	3,673	6.82	5,256	6.32	2,911	6.02	21	16,178
Gonorrhea††	95	2.60	81	0.54	3,229	7.88	232,171	529.02	270,232	397.11	85,730	82.25	3,599	6.07	6,125	601,262
Haemophilus influenzae, invasive disease																
Age <5 years																
Non-b serotype	68	1.86	71	0.48	—	—	—	—	—	—	—	—	—	—	—	139
Nontypeable	157	4.30	98	0.66	—	—	—	—	—	—	—	—	—	—	—	255
Serotype b	26	0.71	8	0.05	—	—	—	—	—	—	—	—	—	—	—	34
Unknown serotype	119	3.26	109	0.73	—	—	—	—	—	—	—	—	—	—	—	228
All ages, all serotypes	370	10.14	286	1.92	198	0.48	190	0.43	606	0.89	1,689	1.62	3,484	5.88	4	6,827
Hansen's disease	—	—	—	—	—	—	7	0.02	21	0.03	31	0.03	29	0.05	—	88
Hantavirus infection, non-hantavirus pulmonary syndrome‡‡	—	—	—	—	—	—	—	—	—	—	—	—	1	0.00	—	1
Hantavirus pulmonary syndrome	—	—	—	—	1	0.00	2	0.00	6	0.01	12	0.01	5	0.01	—	26
Hemolytic uremic syndrome post-diarrheal	7	0.20	122	0.87	68	0.18	17	0.04	10	0.02	31	0.03	21	0.04	—	276
Hepatitis, Viral Disease§§																
Hepatitis A, acute	1	0.03	25	0.17	59	0.14	167	0.38	576	0.85	590	0.57	225	0.38	—	1,643
Hepatitis B, acute	—	—	—	—	1	0.00	102	0.23	472	0.69	1,261	1.21	374	0.63	2	2,212
Hepatitis B, perinatal infection	3	NC	4	NC	—	NC	—	NC	—	NC	—	NC	—	NC	—	7
Hepatitis C, acute																
Confirmed	1	0.03	1	0.01	5	0.01	377	0.88	2,100	3.16	2,007	1.97	471	0.82	2	4,964
Probable	—	—	—	—	1	0.00	28	0.07	224	0.34	237	0.23	84	0.15	—	574
Total	1	0.03	1	0.01	6	0.02	405	0.95	2,324	3.50	2,244	2.20	555	0.96	2	5,538

TABLE 4. Annual reported cases of notifiable diseases and rates, by age group, United States, excluding U.S. Territories and Non-U.S. Residents, 2023

Disease	<1 yr		1-4 yrs		5-14 yrs		15-24 yrs		25-39 yrs		40-64 yrs		65+ yrs		Age not stated	Total
	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	No.
Hepatitis C, perinatal infection	99	NC	136	NC	—	NC	—	NC	—	NC	—	NC	—	NC	—	235
Human immunodeficiency virus diagnoses	29	0.79	11	0.07	39	0.10	7,095	16.17	19,293	28.35	11,426	10.96	957	1.62	—	38,850
Influenza-associated pediatric mortality	20	0.55	48	0.32	64	0.16	10	0.07	—	—	—	—	—	—	—	142
Invasive pneumococcal disease																
Age <5 years																
Confirmed	308	10.42	806	6.69	—	—	—	—	—	—	—	—	—	—	—	1,114
Probable	16	0.54	51	0.42	—	—	—	—	—	—	—	—	—	—	—	67
Total	324	10.97	857	7.12	—	—	—	—	—	—	—	—	—	—	—	1,181
All ages																
Confirmed	293	10.62	760	6.78	725	2.36	319	0.97	1,974	3.91	7,958	10.18	8,490	18.85	32	20,551
Probable	14	0.51	47	0.42	72	0.23	11	0.03	44	0.09	194	0.25	218	0.48	—	600
Total¶¶	307	11.13	807	7.19	797	2.59	330	1.00	2,018	4.00	8,152	10.42	8,708	19.33	32	21,151
Legionellosis	3	0.08	3	0.02	7	0.02	36	0.08	520	0.76	3,499	3.36	4,030	6.80	3	8,101
Leptospirosis	—	—	—	—	2	0.01	8	0.02	30	0.06	35	0.04	19	0.04	—	94
Listeriosis##																
Confirmed	44	1.21	4	0.03	3	0.01	15	0.03	62	0.09	218	0.21	586	0.99	2	934
Probable	7	0.19	—	—	1	0.00	3	0.01	28	0.04	9	0.01	16	0.03	—	64
Total	51	1.40	4	0.03	4	0.01	18	0.04	90	0.13	227	0.22	602	1.02	2	998
Lyme disease***																
Confirmed	2	0.06	168	1.14	713	1.75	289	0.66	499	0.74	1,171	1.13	687	1.17	1	3,530
Probable	18	0.50	1,540	10.41	8,484	20.78	6,320	14.45	11,328	16.72	30,983	29.85	27,248	46.23	17	85,938
Total	20	0.55	1,708	11.54	9,197	22.53	6,609	15.12	11,827	17.45	32,154	30.98	27,935	47.39	18	89,468
Malaria	3	0.08	68	0.46	213	0.52	378	0.86	759	1.12	952	0.91	232	0.39	1	2,606
Measles†††																
Imported	4	0.11	7	0.05	3	0.01	4	0.01	2	0.00	2	0.00	—	—	—	22
Indigenous	4	0.11	13	0.09	9	0.02	13	0.03	3	0.00	—	—	—	—	—	42
Total	8	0.22	20	0.13	12	0.03	17	0.04	5	0.01	2	0.00	—	—	—	64
Melioidosis‡‡‡	—	—	—	—	—	—	—	—	—	—	3	0.00	3	0.01	—	6
Meningococcal disease																
All serogroups	12	0.33	17	0.11	8	0.02	45	0.10	87	0.13	185	0.18	84	0.14	—	438
Other serogroups	1	0.03	—	—	—	—	12	0.03	7	0.01	9	0.01	4	0.01	—	33
Serogroup B	3	0.08	6	0.04	1	0.00	11	0.03	7	0.01	11	0.01	5	0.01	—	44
Serogroups ACWY	3	0.08	8	0.05	3	0.01	7	0.02	61	0.09	127	0.12	51	0.09	—	260
Unknown serogroup	5	0.14	3	0.02	4	0.01	15	0.03	12	0.02	38	0.04	24	0.04	—	101
Mpox	1	0.03	1	0.01	—	—	168	0.38	1,005	1.48	511	0.49	10	0.02	34	1,730
Mumps	7	0.19	97	0.65	111	0.27	34	0.08	46	0.07	88	0.08	49	0.08	1	433
Novel Influenza A virus infections	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3	3
Pertussis	830	22.75	1,484	9.98	1,891	4.61	1,054	2.40	420	0.62	877	0.84	497	0.84	10	7,063
Plague§§§	—	—	—	—	—	—	—	—	—	—	1	0.00	1	0.00	—	2
Poliomyelitis, paralytic	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Poliovirus infection, nonparalytic	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Psittacosis	—	—	—	—	—	—	—	—	—	—	—	—	1	0.00	—	1
Q fever																
Acute	—	—	1	0.01	1	0.00	7	0.02	31	0.05	74	0.07	67	0.11	—	181
Chronic	—	—	—	—	—	—	2	0.00	2	0.00	17	0.02	17	0.03	—	38
Total	—	—	1	0.01	1	0.00	9	0.02	33	0.05	91	0.09	84	0.14	—	219
Rabies																
Human	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Rubella	—	—	1	0.01	2	0.00	2	0.00	4	0.01	2	0.00	—	—	—	11

TABLE 4. Annual reported cases of notifiable diseases and rates, by age group, United States, excluding U.S. Territories and Non-U.S. Residents, 2023

Disease	<1 yr		1-4 yrs		5-14 yrs		15-24 yrs		25-39 yrs		40-64 yrs		65+ yrs		Age not stated	Total
	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	No.
Rubella, congenital syndrome	1	0.03	—	—	—	—	—	—	—	—	—	—	—	—	—	1
Salmonella Paratyphi infection¶¶¶	—	—	13	0.09	36	0.09	25	0.06	49	0.07	41	0.04	17	0.03	—	181
Salmonella Typhi infection###	3	0.08	39	0.26	119	0.29	91	0.21	157	0.23	106	0.10	20	0.03	—	535
Salmonellosis (excluding *S. Typhi* infection and *S. Paratyphi* infection)****	5,028	137.80	6,934	46.65	4,996	12.19	4,692	10.69	8,773	12.89	16,619	15.94	13,854	23.38	38	60,934
Severe acute respiratory syndrome-associated coronavirus disease	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Shiga toxin-producing *Escherichia coli* (STEC)	568	15.57	2,636	17.74	1,861	4.54	2,379	5.42	3,329	4.89	4,386	4.21	3,677	6.21	8	18,844
Shigellosis	215	5.89	2,793	18.79	2,127	5.19	1,819	4.14	5,675	8.34	6,638	6.37	2,484	4.19	18	21,769
Smallpox	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Spotted fever rickettsiosis																
Confirmed	—	—	2	0.01	2	0.00	2	0.00	5	0.01	27	0.03	18	0.03	—	56
Probable	1	0.03	22	0.15	44	0.11	55	0.13	174	0.26	508	0.49	344	0.58	—	1,148
Total	1	0.03	24	0.16	46	0.11	57	0.13	179	0.26	535	0.52	362	0.62	—	1,204
Streptococcal toxic shock syndrome	5	0.22	21	0.22	54	0.21	28	0.10	113	0.26	368	0.55	302	0.78	—	891
Syphilis																
Congenital††††	3,882	106.40	—	—	—	—	—	—	—	—	—	—	—	—	—	3,882
Primary and secondary	1	0.03	4	0.03	53	0.13	9,222	21.01	26,649	39.16	16,037	15.39	1,020	1.72	2	52,988
Total‡‡‡‡	3,888	106.56	6	0.04	140	0.34	32,236	73.45	106,215	156.09	62,035	59.52	4,572	7.72	27	209,119
Tetanus	—	—	—	—	1	0.00	2	0.00	6	0.01	6	0.01	3	0.01	—	18
Toxic shock syndrome (other than Streptococcal)	1	0.04	1	0.01	7	0.02	12	0.04	4	0.01	9	0.01	5	0.01	—	39
Trichinellosis	—	—	—	—	—	—	—	—	—	—	1	0.00	—	—	—	1
Tuberculosis	60	1.64	171	1.15	235	0.57	1,021	2.33	2,356	3.46	3,260	3.13	2,528	4.27	2	9,633
Tularemia	—	—	8	0.05	11	0.03	12	0.03	42	0.06	75	0.07	48	0.08	—	196
Vancomycin-intermediate *Staphylococcus aureus*	1	0.03	2	0.02	1	0.00	2	0.01	7	0.01	17	0.02	29	0.06	—	59
Vancomycin-resistant *Staphylococcus aureus*§§§§	—	—	—	—	—	—	1	0.00	—	—	—	—	—	—	—	1
Varicella morbidity¶¶¶¶	626	20.57	1,295	10.43	2,297	6.70	923	2.51	890	1.57	425	0.49	58	0.12	382	6,896
Varicella mortality	U	U	U	U	U	U	U	U	U	U	U	U	U	U	U	U
Vibriosis																
Confirmed	3	0.08	28	0.19	90	0.22	107	0.25	276	0.41	587	0.57	451	0.77	—	1,542
Probable	18	0.50	50	0.34	63	0.16	117	0.27	320	0.48	683	0.67	628	1.08	1	1,880
Total	21	0.59	78	0.53	153	0.38	224	0.52	596	0.89	1,270	1.24	1,079	1.85	1	3,422
Viral hemorrhagic fevers																
Chapare virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Crimean-Congo hemorrhagic fever virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Ebola virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Guanarito virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Junin virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Lassa virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Lujo virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Machupo virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Marburg virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

TABLE 4. Annual reported cases of notifiable diseases and rates, by age group, United States, excluding U.S. Territories and Non-U.S. Residents, 2023

Disease	<1 yr		1-4 yrs		5-14 yrs		15-24 yrs		25-39 yrs		40-64 yrs		65+ yrs		Age not stated	Total
	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	No.
Sabia virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Yellow fever	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Zika virus																
Zika virus disease, congenital####	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Zika virus disease, non-congenital	—	—	—	—	—	—	—	—	4	0.01	2	0.00	—	—	—	6
Zika virus infection, congenital####	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Zika virus infection, non-congenital	—	—	—	—	—	—	—	—	1	0.00	—	—	—	—	—	1

—: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
NC: Not Calculated — There is insufficient data available to support this statistic.
U: Unavailable — The data are unavailable.

* Beginning in 2023, only confirmed cases of *Candida auris* clinical are published to align with CSTE position statement 22-ID-05, whereas in previous years, confirmed and probable case classification statuses were published. Additionally, there may be case count discrepancies of *Candida auris* clinical cases reported by the NNDSS and the CDC's Mycotic Diseases Branch due to differences in data sources, reporting and aggregation methods. Please refer to the Mycotic Diseases Branch's Tracking C. auris | Candida auris (C. auris) | CDC for *Candida auris* case data reported by jurisdictions. These data are submitted to the CDC separately of NNDSS by jurisdictions and are published by location of the facility. Please also see Note #8.
† Beginning in 2023, *Candida auris* screening was added as a nationally notifiable condition, and confirmed cases are published to align with the approved CSTE position statement 22-ID-05. Additionally, there may be case count discrepancies of *Candida auris* screening cases reported by the NNDSS and the CDC's Mycotic Diseases Branch due to differences in data sources, reporting and aggregation methods. Please refer to the Mycotic Diseases Branch's Tracking C. auris | Candida auris (C. auris) | CDC for *Candida auris* case data reported by jurisdictions. These data are submitted to the CDC separately of NNDSS by jurisdictions and are published by location of the facility. Please also see Note #8.
‡ Beginning in 2023, cases began to be reported as carbapenemase-producing organisms, clinical or carbapenemase-producing organisms, screening. In previous years, only carbapenemase-producing carbapenem-resistant *Enterobacteriaceae* (CP-CRE) cases were reported.
§ CPO total is the sum of CP-CRE cases reported in MMWR year 2023, CPO, clinical cases, and CPO, screening cases.
¶ For coccidioidomycosis surveillance reporting purposes, jurisdictions are grouped into high- and low-incidence categories. Probable cases are only reported from low-incidence jurisdictions, while confirmed cases are reported from both high- and low-incidence jurisdictions.
# Of the reporting areas that submitted 2023 aggregate COVID-19 data to CDC, four did not submit probable cases. American Samoa, Commonwealth of Northern Mariana Islands, New York (excluding New York City), and U.S. Virgin Islands did not collect probable cases.
** Counts include confirmed and probable dengue cases.
†† Beginning in 2023, confirmed and probable cases of gonorrhea are published to align with the approved CSTE position statement 22-ID-03, whereas in previous years, all case classification statuses were published. This change may cause a decrease in published case counts when compared to previous years.
‡‡ Case counts may include Old World hantavirus infections, such as Seoul virus.
§§ Chronic hepatitis B and chronic hepatitis C data are not included in NNDSS tables but reported case counts are included in the annual Viral Hepatitis Surveillance Report, 2023, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/php/statistics-surveillance/.
¶¶ Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named *Streptococcus pneumoniae* invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
Before 2019, probable cases were not reported, and cases in neonates ≤60 days of age were counted as one case in a mother-infant pair. Beginning in 2019, confirmed and probable cases are being reported, and maternal and neonatal cases are being counted separately.
*** For Lyme surveillance reporting purposes, jurisdictions are grouped into high- and low-incidence categories. Confirmed cases are only reported from low-incidence jurisdictions; however, probable cases are reported from both high- and low-incidence jurisdictions. For more information on jurisdiction classifications, visit https://www.cdc.gov/lyme. Currently high-incidence jurisdictions include Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York (excluding New York City), New York City, Pennsylvania, Rhode Island, Vermont, Virginia, West Virginia, Wisconsin, and the District of Columbia.
††† Measles is considered imported if the disease was acquired outside of the United States and is considered indigenous if the disease was acquired anywhere within the United States or it is not known where the disease was acquired.
‡‡‡ Beginning in 2023, melioidosis was added as a nationally notifiable condition, and confirmed and probable cases are published to align with the approved CSTE position statement 22-ID-08.
§§§ Beginning in 2020, confirmed and probable plague cases began to be combined and published.
¶¶¶ Beginning in January 2019, cases began to be reported as *Salmonella* Paratyphi infection. In 2018, cases were reported as paratyphoid fever. Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
Beginning in January 2019, cases began to be reported as *Salmonella* Typhi infection. In previous years, cases were reported as typhoid fever.
**** Beginning in January 2019, cases began to be reported as salmonellosis (excluding *Salmonella* Typhi infection and *Salmonella* Paratyphi infection). In 2018, cases were reported as salmonellosis (excluding paratyphoid fever and typhoid fever). Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
†††† Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. Data for congenital syphilis are aggregated by the infant's year of birth.
‡‡‡‡ Includes the following categories: primary; secondary; early non-primary non-secondary; unknown duration or late; and congenital syphilis.
§§§§ Vancomycin-resistant *Staphylococcus aureus* cases reported in this table may not have been verified by CDC. CDC verified 0 vancomycin-resistant *Staphylococcus aureus* cases in 2023.
¶¶¶¶ Beginning in 2023, varicella mortality will have an age restriction of <50 years applied to the numerator (i.e., case counts).
Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01).

Notes:

1. These are **annual** cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2023 annual tables were officially closed on November 7, 2024.

2. The list of national notifiable Infectious diseases and conditions for 2023 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2023" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". Publication criteria for the finalized 2023 data are available at https://www.cdc.gov/nndss/infectious-disease/notice-to-data-users.html. See also Guide to Interpreting Provisional and Finalized NNDSS Data.

3. Population estimates for incidence rates are July 1st, 2023 postcensal estimates of the resident population of the United States for July 1, 2020, to July 1, 2023, by year, county, single year of age (range: 0 to 85+ years), bridged-race (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), Hispanic ethnicity (Hispanic or Latino, not Hispanic or Latino), and sex (Female, Male), prepared under a collaborative arrangement with the U.S. Census Bureau and the National Cancer Institute (NCI). The "Vintage 2023" population estimates for years 2020–2023 were released February 2025 by the National Cancer Institute at https://seer.cancer.gov/popdata/. For more information, see https://seer.cancer.gov/popdata/singleages.html. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.

4. Annual tables for 2016 and later years are available on CDC WONDER's NNDSS Annual Summary Data Query.

5. Annual summary reports from 1993–2015 are available as published in the *Morbidity and Mortality Weekly Report*.

6. NNDSS annual tables since 1952 are available at CDC Stacks. To find them, search for "NNDSS" under Collections. Once in NNDSS Collections, navigate to the "Resource Type Specific" section on the left-hand side and select "Annual Reports" (1952–2015) or "Annual Tables" (2016–present).

7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

Age restrictions in the numerator and denominator are applied for the following childhood conditions:

Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
Infant botulism (age restriction in numerator and denominator is <1 year)
Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
Perinatal hepatitis B infection (age restriction in numerator is ≤24 months; however, rates will not be calculated due to population estimates not being available for the specific sub-population required to align with the defined age restriction criteria)
Perinatal hepatitis C infection (age restriction in numerator is ≤36 months; however, rates will not be calculated due to population estimates not being available for the specific sub-population required to align with the defined age restriction criteria).

Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2023 (National Center for Health Statistics Natality 2023, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).

Suggested Citation:

Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2023 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Office of Public Health Data, Surveillance, and Technology, 2025. Available at: https://www.cdc.gov/nndss/infectious-disease/.

Acknowledgment:

CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.